Comparative Pharmacology
Head-to-head clinical analysis: STANOZIDE versus WINSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STANOZIDE versus WINSTROL.
STANOZIDE vs WINSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; increases protein synthesis and muscle mass by binding to androgen receptors, leading to enhanced nitrogen retention and erythropoiesis.
Winstrol (stanozolol) is an anabolic steroid derived from dihydrotestosterone. It binds to androgen receptors, increasing protein synthesis and inhibiting catabolic glucocorticoid activity, leading to enhanced muscle growth and reduced inflammation.
100 mg orally twice daily or 200 mg orally once daily; immediate-release formulation.
Adults: 2 mg orally three times daily, or 50 mg/mL intramuscularly once monthly (3-4 week intervals) for anabolic effect. Dose range: 1-3 mg/kg/day for hereditary angioedema.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours, supporting once-daily dosing. Clinical context: Steady-state achieved after approximately 5-7 days.
Terminal elimination half-life: 9-10 hours for oral administration (stanozolol); parenteral (IM) half-life extends to ~24 hours due to slow release from injection site. Clinical context: supports once-daily oral dosing or weekly IM dosing.
Primarily hepatic metabolism (approximately 80%) with biliary excretion of metabolites; renal excretion of unchanged drug is minimal (<5%). Fecal elimination accounts for <15%.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates) and 10% as unchanged drug; minor biliary/fecal elimination (<5%).
Category C
Category C
Anabolic Steroid
Anabolic Steroid